/**

Dentalkart in FY26: Growth held up, but margins and cash flow took a hit

Dentalkart, operated by Vasa Denticity Limited and listed on NSE Emerge as DENTALKART, closed FY26 with steady topline growth and a sharp rise in customer activity. Consolidated revenue from operations grew to INR 278.87 crore, up 11.8% year on year. Total income, including other income, was INR 283.39 crore, up 12.8%.

But FY26 was not a clean compounding year. Profitability weakened sharply in the second half. Consolidated reported EBITDA fell to INR 15.43 crore from INR 24.86 crore, and PAT declined to INR 10.24 crore from INR 16.97 crore. The company attributes the margin compression to own-brand availability issues and INR depreciation, both of which worsened gross margins materially in H2.

A year of customer expansion, with Q4 showing the strain

Operationally, Dentalkart continued to add customers at a rapid pace. FY26 unique customers increased 27.8% to 1.44 lakh. Orders shipped rose 26.2% to 7.60 lakh. The FY26 new-customer count was 70,746, up 61.8%.

The Q4 picture was mixed. Total income rose to INR 75.30 crore, up 2.9% YoY, but revenue from operations was largely flat at INR 73.26 crore. Orders still grew 14.5% YoY to 1.85 lakh, while average order value fell to about INR 3,914. Profitability in Q4 was particularly weak on an operating basis. Reported EBITDA of INR 2.32 crore was supported by other income of INR 2.04 crore, leaving operating EBITDA at just INR 0.28 crore.

Segment mix improved on paper, but supply issues hit at the wrong time

FY26 included a deliberate pruning of a low-strategic-value business line. The company exited other-brand offline trading, which contributed INR 39.0 crore in FY25 and went to zero in FY26. Excluding this exited segment, management presents like-for-like growth of 33% YoY, with continuing operations rising from INR 210.4 crore to INR 278.9 crore.

In the continuing business, the online consumer segment remained the core driver. Dentalkart online revenue grew from INR 185.2 crore to INR 232.2 crore. Own brand offline revenue, which includes Waldent and the Digital Dentistry business, rose from INR 25.2 crore to INR 46.7 crore.

Despite exiting a low-margin line, headline margins compressed because the gross margin decline in H2 was severe. The company reports gross margin of 33.5% in Q1 and 33.9% in Q2, but only 28.5% in Q3 and 23.7% in Q4. Management links this to a lower own-brand mix caused by stockouts and to higher landed costs due to INR depreciation.

This matters because the company positions own brands as its margin engine. It claims own brands are structurally higher margin than distributed brands and offer pricing control and supply advantages. FY26, however, showed how sensitive blended margins can be when own-brand availability weakens.

Cash flow and working capital: the main operational test for FY27

The biggest stress point in the financials is operating cash flow. FY26 cash from operations was negative INR 25.09 crore, even though PBT was positive at INR 13.19 crore. The company explains this primarily through inventory build. Inventory stood at INR 81.16 crore at 31 March 2026, and it highlights an inventory build of about INR 27.45 crore year on year, tied to exclusive own-brand deals.

To address this, Dentalkart lays out a specific inventory-days glide path: 120 to 150 days in FY27, 90 to 120 days in FY28, and below 100 days longer term. The intent is clear. A normalization in inventory should improve cash conversion, but the timeline and pace will be key for investor confidence.

The balance sheet remains supportive. As of 31 March 2026, the company reported cash and equivalents of INR 4.80 crore and current investments of INR 42.47 crore. Net cash was INR 47.15 crore (cash plus liquid investments minus short-term borrowings). This buffer gives the company time to fix supply and working-capital discipline without taking on meaningful leverage.

Strategy updates: Digital Dentistry and a clear pause on M&A

Two strategic themes stand out in the deck.

First is the Digital Dentistry Division, launched in September 2025. The company describes it as a vertical for high-ticket clinic-grade equipment such as intraoral scanners, CAD/CAM milling, 3D printing, sterilisation and imaging. It cites India digital dentistry adoption at about 4% versus a global average near 40% and suggests that clinics adopting digital workflows have 5 to 10 times the lifetime value of consumables-only buyers. In Q4 FY26, it reports an average invoice ticket of INR 6.97 lakh, indicating the business is oriented toward fewer but higher-value transactions.

Second is the mutual withdrawal of the proposed IDS Denmed acquisition in May 2026. The company states that the integration overhead would be disproportionate to near-term value and that there was no material transaction-related financial impact. It also states that FY27 is intended to be a year of deep operating focus on dentalkart.com with no major inorganic transaction planned.

What the presentation signals for FY27

The investor update is unusually direct about what went wrong and what needs fixing. It includes a promises-versus-delivered tracker, acknowledging misses on margin normalization, delivery time targets, and quarterly video earnings calls.

On forward direction, management states that FY27 gross margin is expected to move toward 30 to 33% as availability improves, subject to FX and pricing actions. It also targets mid-teens operating EBITDA margin within 2 to 3 years.

Execution will be judged on a small set of operating lines: gross margin recovery after stockouts, inventory-days reduction after a large working-capital build, and delivery turnaround time, which the company reports at about 4.2 days with a stated ambition of below 48 hours nationally.

Dentalkart exited a low-margin segment and grew its core customer engine in FY26, but the year also exposed the operational fragility that can come with private-label dependence and imported SKU exposure. FY27, by the company’s own framing, is the year where this growth has to translate back into predictable operating EBITDA and improved cash conversion.

*/